Byron P. Vaughn - Concepedia

Author

Byron P. Vaughn

Also Known As

Altayar, Osama, Andres J. Yarur, B. P. Vaughn, B. Vaughn, Byron P Vaughn, Byron P. Vaughn, Byron Philip Vaughn, Byron Vaughn, Vaughn, Byron

172

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

University of Minnesota Beth Israel Deaconess Medical Center Biotechnology Institute Harvard University University of Minnesota Medical Center

About

Byron P. Vaughn is an author at University of Minnesota specializing in medicine, gastroenterology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	1.1K
2	Engineering	1	1	51
3	Public Health	1	1	20
4	Allergy	1	1	32
5	Biostatistics	1	1	51

Byron P. Vaughn

Publications

Citations

H-Index

Page 1

	Year	Citations
Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study Christopher Staley, Matthew J. Hamilton, Byron P. Vaughn, The American Journal of Gastroenterology	2017	236
Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab Konstantinos Papamichael, Karen A. Chachu, Ravy K. Vajravelu, Clinical Gastroenterology and Hepatology InflammationAnti-inflammatoryImmunologyGastroenterologyUlcerative Colitis	2017	218
Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohnʼs Disease Byron P. Vaughn, Tommi Vatanen, Jessica R. Allegretti, Inflammatory Bowel Diseases	2016	215
Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease Byron P. Vaughn, Manuel Martínez-Vazquez, Vilas Patwardhan, Inflammatory Bowel Diseases	2014	211
Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection Alexander Khoruts, Kevin Rank, Krista M. Newman, Clinical Gastroenterology and Hepatology ProbioticDysbiosisIntestinal TransplantationImmunologyGastroenterology	2016	210
AGA Clinical Practice Guideline on Fecal Microbiota–Based Therapies for Select Gastrointestinal Diseases Anne F. Peery, Colleen Kelly, Dina Kao, Gastroenterology	2024	162
Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease Konstantinos Papamichael, Anna C. Juncadella, Danny Wong, Journal of Crohn s and Colitis	2019	140
Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease Konstantinos Papamichael, Ravy K. Vajravelu, Byron P. Vaughn, Journal of Crohn s and Colitis	2018	114
High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines Kathryn A. Pape, Thamotharampillai Dileepan, Amanda J. Kabage, Cell Reports	2021	108
A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis Byron P. Vaughn, Thomas Kaiser, Christopher Staley, Clinical and Experimental Gastroenterology	2019	101

Page 1